Jade Biosciences, Inc. (JBIO) Form 8-K — Jun 26, 2026
$JBIOForm 8-KItems 5.02, 7.01, 9.01Filed Jun 26, 2026, 7:15 AM ET0001193125-26-283906Original filing
Jade Biosciences appointed Mark Eisner, M.D., M.P.H. to its Board of Directors as a Class I director effective June 25, 2026. Dr. Eisner brings over 25 years of experience in clinical development and immunology, having previously served as Chief Medical Officer at Vir Biotechnology and in senior roles at Genentech and FibroGen.
Key figures
- Board Class
- Class I
- Options Granted
- 47675
- Vesting Period Years
- 3
Price after filing
1 day: 0.0%7 days: -1.4%30 days: -10.0%
Close on the filing date to close N calendar days later (from $21.81). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.